Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

oral

NASH, PUBLICATIONS

Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis

By charlie maddox / 06/2024

EASL International Liver Congress

Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model

By Graviton / 11/2023

7th Obesity and NASH Drug Development Summit

Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial

By Lehi Vidigal / 06/2023

EASL International Liver Congress

Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH

By Graviton / 11/2022

AASLD The Liver Meeting

TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response

By Graviton / 11/2021

NASH Summit

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China

By Graviton / 11/2021

AASLD The Liver Meeting

Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH

By Graviton / 09/2021

NASH and Fibrosis Conference

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

By Graviton / 11/2020

AASLD

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

By Graviton / 09/2020

European Society for Medical Oncology (ESMO) Congress

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

By Graviton / 08/2020

EASL International Liver Congress

Post pagination

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2024 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

Scroll to Top